Pharmacological inhibition of 17β-hydroxysteroid dehydrogenase impairs human endometrial cancer growth in an orthotopic xenograft mouse model.

[1]  L. Massuger,et al.  Oestrogen receptor pathway activity is associated with outcome in endometrial cancer , 2020, British Journal of Cancer.

[2]  Romi Gupta,et al.  Identification of the Mutational Landscape of Gynecological Malignancies , 2020, Journal of Cancer.

[3]  N. Colombo,et al.  Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study , 2020, International journal of molecular sciences.

[4]  S. Liang,et al.  Dusp6 Inhibits Epithelial-mesenchymal Transition in Endometrial Adenocarcinoma Via ERK Signaling Pathway , 2019, Radiology and oncology.

[5]  Y. Zhuang,et al.  Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism , 2019, Cell Communication and Signaling.

[6]  G. Siegwart,et al.  Sprouty3 and Sprouty4, Two Members of a Family Known to Inhibit FGF-Mediated Signaling, Exert Opposing Roles on Proliferation and Migration of Glioblastoma-Derived Cells , 2019, Cells.

[7]  P. Beale,et al.  Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903. , 2019, Gynecologic oncology.

[8]  M. Poutanen,et al.  Role of hydroxysteroid (17beta) dehydrogenase type 1 in reproductive tissues and hormone-dependent diseases , 2019, Molecular and Cellular Endocrinology.

[9]  A. Romano,et al.  Local estrogen metabolism (intracrinology) in endometrial cancer: A systematic review , 2019, Molecular and Cellular Endocrinology.

[10]  A. Romano,et al.  Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review , 2019, Front. Oncol..

[11]  X. Fang,et al.  Epigenetically Down-Regulated Acetyltransferase PCAF Increases the Resistance of Colorectal Cancer to 5-Fluorouracil1 , 2019, Neoplasia.

[12]  Kristofer C. Berrett,et al.  ETV4 is necessary for estrogen signaling and growth in endometrial cancer cells , 2019, bioRxiv.

[13]  H. Mackay,et al.  Endocrine therapy in endometrial cancer: An old dog with new tricks. , 2019, Gynecologic oncology.

[14]  Sheng-Xiang Lin,et al.  siRNA-based breast cancer therapy by suppressing 17β-hydroxysteroid dehydrogenase type 1 in an optimized xenograft cell and molecular biology model in vivo , 2019, Drug design, development and therapy.

[15]  M. Ramström,et al.  Molecular characterization of PRM-associated endometrial changes, PAEC, following mifepristone treatment. , 2018, Contraception.

[16]  S. Xanthoulea,et al.  Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery , 2018, Front. Pharmacol..

[17]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[18]  L. Dubois,et al.  Development of an Image-Guided Orthotopic Xenograft Mouse Model of Endometrial Cancer with Controllable Estrogen Exposure , 2018, International journal of molecular sciences.

[19]  A. Talhouk,et al.  Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  T. Lakka,et al.  Analysis by LC–MS/MS of endogenous steroids from human serum, plasma, endometrium and endometriotic tissue , 2018, Journal of pharmaceutical and biomedical analysis.

[21]  Jia Gu,et al.  fastp: an ultra-fast all-in-one FASTQ preprocessor , 2018, bioRxiv.

[22]  S. Xanthoulea,et al.  Blocking 17β‐hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach , 2018, The Journal of pathology.

[23]  Samuel Leung,et al.  Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification , 2017, The journal of pathology. Clinical research.

[24]  E. Crosbie,et al.  Biomarkers needed to predict progestin response in endometrial cancer , 2017, BJOG : an international journal of obstetrics and gynaecology.

[25]  Tiandao Li,et al.  Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis , 2016, Nucleic acids research.

[26]  P. Leung,et al.  Sprouty2 inhibits amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells , 2016, Oncotarget.

[27]  M. Beckmann,et al.  Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. , 2015, Endocrine-related cancer.

[28]  M. Munsell,et al.  Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[30]  Jun Tan,et al.  KITLG is a novel target of miR-34c that is associated with the inhibition of growth and invasion in colorectal cancer cells , 2014, Journal of cellular and molecular medicine.

[31]  K. Thiel,et al.  Past, present, and future of hormonal therapy in recurrent endometrial cancer , 2014, International journal of women's health.

[32]  I. Vergote,et al.  Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO) , 2014, BMC Cancer.

[33]  Lincoln D. Stein,et al.  Identification of genes expressed by immune cells of the colon that are regulated by colorectal cancer-associated variants , 2013, International journal of cancer.

[34]  M. Pike,et al.  Type I and II endometrial cancers: have they different risk factors? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Lambeir,et al.  The potential of carboxypeptidase M as a therapeutic target in cancer , 2013, Expert opinion on therapeutic targets.

[36]  Ralf Herwig,et al.  The ConsensusPathDB interaction database: 2013 update , 2012, Nucleic Acids Res..

[37]  R. López-López,et al.  ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas , 2012, Oncogene.

[38]  A. Romano,et al.  Overexpression of 17β-hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17β-estradiol. , 2012, The Journal of clinical endocrinology and metabolism.

[39]  R. Bast,et al.  The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways , 2012, Oncogene.

[40]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[41]  J. Brosens,et al.  Novel hydroxysteroid (17beta) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice. , 2010, The American journal of pathology.

[42]  B. Husen,et al.  Estrone C15 derivatives—A new class of 17β-hydroxysteroid dehydrogenase type 1 inhibitors , 2009, Molecular and Cellular Endocrinology.

[43]  M. Poutanen,et al.  Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts. , 2006, Endocrinology.

[44]  M. Poutanen,et al.  Evaluation of inhibitors for 17β-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme , 2006, Molecular and Cellular Endocrinology.

[45]  A. Romano,et al.  Inhibition of type 1 17β-hydroxysteroid dehydrogenase impairs the synthesis of 17β-estradiol in endometriosis lesions. , 2014, The Journal of clinical endocrinology and metabolism.

[46]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[47]  G. Bhagat,et al.  TGFBI deficiency predisposes mice to spontaneous tumor development. , 2009, Cancer research.